COVID-19 vaccination in Switzerland

Last updated

COVID-19 vaccination in Switzerland
DateDecember 22, 2021 (2021-12-22) – present
Location Switzerland
Cause COVID-19 pandemic in Switzerland

COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

By 5 November 2021, 11,178,041 doses of COVID-19 vaccine have been administered. [1]

Background

Lonza Group in Visp where the Moderna COVID-19 vaccine is produced. Site Lonza de Viege, vu depuis la gare de Lalden 2.JPG
Lonza Group in Visp where the Moderna COVID-19 vaccine is produced.

On 19 December 2020, the Swiss Agency for Therapeutic Products (Swissmedic) approved the Pfizer–BioNTech COVID-19 vaccine (Comirnaty) for regular use, two months after receiving the application, although it was expected to give a decision later than other European countries, as Swiss laws do not allow emergency approvals. After the application was processed with high priority using all the available resources, head of Swissmedic stated that the vaccine fully complied with the requirements of safety, efficacy and quality. This constituted the first authorization by a stringent regulatory authority under a standard procedure for any COVID-19 vaccine. [2] [3] Three days later, 107 000 vaccine shots were received by the army to be dispatched in the cantons. On 23 December, 302 days after the first official case, the first patient, a 90-year-old woman from Central Switzerland, was vaccinated in a retirement home in Lucerne. [4] On that day, the cantons of Lucerne, Zug, Schwyz, Nidwalden and Appenzell Innerrhoden launched the vaccination campaign, [5] marking the beginning of mass vaccination in Switzerland and continental Europe outside Russia. [6] Most cantons followed by 4 January 2021 and all the rest of them by 11 January. By that day, about 0.5% of the population received the Pfizer–BioNTech COVID-19 vaccine. [7]

On 12 January 2021, Swissmedic approved the second COVID-19 vaccine: the mRNA-1273 made by Moderna. [8] [9] The Lonza Group where the vaccine is produced was visited by Federal Councilor Alain Berset the previous day. Up to 800,000 vaccines per day are expected to be produced there. A year after the first COVID-19 outbreak, the number of vaccinated people largely outnumbered the official cases. On 7 March, about 10% of the population received at leat one shot of the two approved vaccines (Pfizer and Moderna) and about 3% were fully vaccinated. [10]

A third vaccine, the Oxford/AstraZeneca vaccine (AZD1222), which comprised 5.3 million of the doses ordered by Swiss authorities, was rejected for approval by the Swiss medical authority, SwissMedic, citing insufficient data. [11]

In March 2021, the Swiss Federal Health Ministry reported that approved vaccine deliveries have increased steadily every month. Switzerland received 1.1 million doses of the Moderna and Pfizer vaccines in January and February 2021, and another 1 million vaccine doses in March, exceeding initial expectations. As of 16 March, there have been 843,974 people taken the first dose of coronavirus vaccine. [12] The country plans to have its 8.6 million residents vaccinated by summer 2021. [13]

In April 2021, there were reports that vaccine administration and production efforts at the Lonza Group plant in Visp have been hampered due to overly stringent immigration rules in Switzerland, reducing the influx of qualified biotech and healthcare workers, particularly with regard to non-EU/EFTA states. The Valais National Council urged the Swiss federal authorities to create exemptions from the current immigration rules for essential biotech industries. [14]

Drive In vaccination in Thun (March 2021) Covid-19-Impfzentrum Thun 01.jpg
Drive In vaccination in Thun (March 2021)

Vaccines on order

VaccineApprovalDeployment
Pfizer–BioNTech Green check.svg December 19, 2020Green check.svg Yes
Moderna Green check.svg January 12, 2021Green check.svg Yes
Janssen Green check.svg March 22, 2021Green check.svg Yes
Novavax Green check.svg December 20, 2021Pending

Related Research Articles

Moderna COVID-19 vaccine RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, codenamed mRNA-1273 and sold under the brand name Spikevax, is a COVID-19 vaccine developed by American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). It is authorized for use in people aged twelve years and older in some jurisdictions and for people eighteen years and older in other jurisdictions to provide protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered as two or three 0.5 mL doses given by intramuscular injection at an interval of at least 28 days apart.

Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

BioNTech German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

COVAX Initiative to provide COVID-19 vaccines

COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO). It is one of the three pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well logistics, country readiness and in-country delivery.

Pfizer–BioNTech COVID-19 vaccine mRNA-based COVID-19 vaccine

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech and for its development collaborated with American company Pfizer, for support with clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Italy Immunization plan against COVID-19 in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

COVID-19 vaccination in Romania started on 27 December 2020. It was announced that the process would be divided into three phases. Medical personnel would be vaccinated first, followed by the population at risk, and finally by the rest of the population. Vaccination was declared free and non-mandatory. As of May 2021, four types of vaccines were authorized to be used in Romania. This is the largest vaccination campaign in the modern history of Romania.

COVID-19 vaccination in Canada COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020 and is currently ongoing.

COVID-19 vaccination in South Africa Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in the United States Plan to immunize against COVID-19

The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020; mass vaccinations began on December 14, 2020. The Moderna vaccine was granted emergency use authorization on December 17, 2020, and the Janssen vaccine was granted emergency use authorization on February 27, 2021. By April 19, 2021, all U.S. states had opened vaccine eligibility to residents aged 16 and over. On May 10, 2021, the FDA approved the Pfizer-BioNTech vaccine for adolescents aged 12 to 15. On August 23, 2021, the FDA granted full approval to the Pfizer–BioNTech vaccine for individuals aged 16 and over.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Indonesia

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks fifth in the world and second in Asia.

COVID-19 vaccination in Bangladesh Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

COVID-19 vaccination in Singapore Plan to immunize against COVID-19

COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore is currently the most-vaccinated country in the world, with more than 88% of its total population having completed their vaccination regimen.

COVID-19 vaccination in Japan

COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded "slow" for its vaccination efforts.

COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.

COVID-19 vaccination in Taiwan Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.

References

  1. "COVID-⁠19 Switzerland | Coronavirus | Dashboard". www.covid19.admin.ch. Retrieved November 7, 2021.
  2. "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). December 19, 2020. Retrieved December 19, 2020.
  3. "COVID-19: Switzerland can start vaccinating vulnerable groups already in December" (Press release). Federal Office of Public Health. December 19, 2020. Retrieved December 19, 2020.
  4. Erni, Salome (December 23, 2020). "90-jährige Luzernerin als erste Person in der Schweiz gegen Corona geimpft". Luzerner Zeitung . Retrieved December 23, 2020.
  5. Brotschi, Markus (December 23, 2020). "Die Impfung ist da – einige Senioren zögern noch". Der Bund . Retrieved December 24, 2020.
  6. Pralong, Julien (December 23, 2020). "La piqûre de l'espoir pratiquée à Lucerne". Heidi.news. Retrieved December 23, 2020.
  7. "Welche Länder wie schnell impfen". srf.ch . January 13, 2020. Retrieved January 14, 2020.
  8. "Swissmedic erteilt Zulassung für Moderna-Impfstoff in der Schweiz". SRF. January 12, 2020. Retrieved January 12, 2020.
  9. "Swissmedic grants authorisation for the COVID-19 vaccine from Moderna". Swissmedic (Press release). January 12, 2020. Retrieved January 12, 2020.
  10. La vaccination progresse en Suisse, mais l'horizon du "tous vaccinés" est encore lointain, rts.ch. Retrieved 07-03-2021. ("Près de 20'000 injections ont lieu tous les jours, ce qui a permis à près de 10% de la population de recevoir au moins une dose, et à 3% d'obtenir les deux requises pour que la couverture vaccinale soit complète.")
  11. "'Insufficient data': Switzerland declines to approve AstraZeneca vaccine". thelocal.ch. AFP/The Local. February 3, 2021. Retrieved February 18, 2021.
  12. "CORONAVIRUS IN THE WORLD AS OF WEDNESDAY 17 MARCH 2021: LATEST CASE AND DEATH TOLLS IN 24H PER COUNTRY". Sortiraparis. Julie M. March 17, 2021. Retrieved March 17, 2021.
  13. Miller, John (9 March 2021). "Switzerland expecting 1 million COVID vaccine doses from Moderna, Pfizer in March". msn.com. Retrieved 13 March 2021.
  14. "How Switzerland’s strict immigration rules might have contributed to slow vaccination rollout". theLocal.ch. Retrieved 28. April 2021.